surpass cvot tirzepatide Frias_Tirzepatide: Overview of SURPASS Trials

More serious but less common risks include pancreatitis, gallbladder disease, acute kidney injury (often secondary to dehydration from gastrointestinal effects), and hypoglycaemia when used with insulin or sulphonylureas

If you are unsure about your dose, talk to your healthcare provider to avoid mistakes

I only recommend a dosage increase if weight loss falls below this threshold or you hit a plateau

Transitioning from tirzepatide to semaglutide This direction receives less clinical attention because it is less common

Thank you to our patients and community for your continued support

The branded product was discontinued in 2008